Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status
- 1 August 2004
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 31 (6) , 679-689
- https://doi.org/10.1016/j.nucmedbio.2004.03.004
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studiesNuclear Medicine and Biology, 2002
- Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trialBlood, 2001
- Anticancer drug targets: growth factors and growth factor signalingJournal of Clinical Investigation, 2000
- 4. Synthesis, biodistribution and dosimetry studies of 123I-labelled Annexin V in mice: A potential SPET-ligand for visualisation of apoptotic cellsNuclear Medicine Communications, 1999
- Epidermal growth factor receptors: critical mediators of multiple receptor pathwaysPublished by Elsevier ,1999
- EGF receptorThe International Journal of Biochemistry & Cell Biology, 1999
- In vivo evaluation in mice and metabolism in blood of human volunteers of [ 123 I]iodo-PK11195: a possible single-photon emission tomography tracer for visualization of inflammationEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- QUANTITATIVE STUDIES OF CYTOLOGICAL DAMAGE IN MOUSE TESTIS PRODUCED BY EXPOSURE TO HEATCanadian Journal of Genetics and Cytology, 1980
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978